MediSapiens Expanding Rapidly Into Precision Medicine and Genomic Diagnostics

- CAMBRIDGE, Massachusetts, May 12, 2015 /PRNewswire/ -- Finland-based bioinformatics software solution developer, MediSapiens Ltd is expanding its operation into developing bioinformatics solutions for personalized medicine and precision diagnostics. The shift in strategic focus is followed by two major collaboration agreements. Earlier this year MediSapiens announced a joint venture with International Cancer Advocacy Network (ICAN) to develop and publish Remission Coach®, a web-based solution that addresses the urgency of cancer management. This innovative solution provides cancer patients with a personalized platform for actively determine the most appropriate clinical trial for that patient's disease and treatment history. Now MediSapiens announces collaboration with Genoscoper Laboratories, leading animal DNA diagnostics laboratory. Genoscoper is the first DNA testing service provider in the world to develop a genome-wide MyDogDNA testing concept for dogs. The company recently announced an exclusive partnership with Mars Veterinary, a division of Mars, Inc., the world's leading pet food and veterinary care provider. Under the partnership between Mars Petcare and Genoscoper, the MyDogDNA testing concept will be introduced to a global audience of dog owners, breeders and animal health professionals. "We are thrilled to work on both of these projects. They are the perfect example on direct applications of genomic data being used productively in the consumer market. MediSapiens has been a forerunner in translating genomic data into knowledge for research use. Now we are shifting our focus more on the clinical and consumer markets, in order to effectively utilize the expertise we've gained within research market. These two collaborations are the first of many applications that make complex biomedical data accessible," says MediSapiens CEO, Dr. Sami Kilpinen. MediSapiens, Inc. (http://www.medisapiens.com) is a bioinformatics company, based in Helsinki, Finland and Cambridge, Massachusetts, with a strong background in pharmaceutical research and translational genomics. The company provides pharmaceutical and biomedical research organizations with tools that help them design more effective personalized drugs against life-threatening diseases. MediSapiens creates powerful and intuitive software platforms to manage, integrate, and visualize complex multi-dimensional datasets, such as genomic sequencing data.  The company's goal is to drive medicine forward by developing tools that provide scientists with a way to quickly analyze and visualize vast amounts of data and turn it into knowledge that fuels innovation. Genoscoper Laboratories is a Finland-based animal diagnostics laboratory established in 1995. Its MyDogDNA testing concept helps explore inherited characteristics in dogs using the world's first genome-wide DNA analysis. The technology uses a comprehensive panel analysis to test for known mutations, and simultaneously records thousands of neutral chromosomal markers that can be used to measure genetic diversity and even locate new mutations associated with other genetic disorders. For further information, please visit http://www.genoscoper.com/en. ICAN, International Cancer Advocacy Network (http://www.askican.org ) is a 501(c)(3) tax-exempt cancer charitable organization based in Phoenix, Arizona, consisting of a small staff and a global network of more than 1100 volunteers.  ICAN's goal for each and every patient is to extend life with the highest achievable quality of life.  Since its inception in 1996, ICAN-working with distinguished medical and cancer researchers on its Physicians, Biomarkers, and Scientific Advisory Councils-has assisted more than 8,000 patients, families, and caregivers throughout the United States, most U.S. Territories, and in 53 countries. ICAN's Personalized Medicine Cancer Case Navigation Programs assist late-stage cancer patients with direct navigation of their cases, customized advocacy and empowerment services, clinical trials research, compassionate use research, and interpretation of their molecular profiling reports.  ICAN handles cancers ranging from the most commonly diagnosed malignancies to the rarest of tumors.